SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) today announced that Pathwork Diagnostics Inc. will begin offering a molecular diagnostic test based on the Affymetrix microarray platform. The Pathwork Tissue of Origin Test is one of the first microarray-based diagnostic tests for cancer in the United States. The test is being made available through the recently CLIA-certified Pathwork® Diagnostics Laboratory.
